Table 2.
Prevalence of hrHPV infection within various histological groups by age.
| Histology | <30 y | 30-49 y | ≥50 y | |||
|---|---|---|---|---|---|---|
| Cases# | Positive (%) | Cases# | Positive (%) | Cases# | Positive (%) | |
| Negative | 5,883 | 3,422 (58.2) | 27,008 | 11040 (40.9) | 13,549 | 5934 (43.8) |
| CIN1 | 2,396 | 2,174 (90.7) | 5,587 | 4909 (87.9) | 2,075 | 1813 (87.4) |
| CIN2/3 | 510 | 481 (94.3) | 2198 | 2040 (92.8) | 1,065 | 981 (92.1) |
| SCC | 14 | 12 (85.7) | 292 | 269 (92.1) | 472 | 448 (94.9) |
| AIS | 5 | 5 (100.0) | 44 | 39 (88.6) | 8 | 6 (75.0) |
| ADC | 6 | 3 (50.0) | 57 | 47 (82.5) | 48 | 28 (58.3) |
| AIS+ CIN2/3 | 18 | 18 (100.0) | 52 | 48 (92.3) | 17 | 14 (82.4) |
| ADSQ | 6 | 6 (100.0) | 44 | 41 (93.2) | 51 | 48 (94.1) |
| SNEC | 2 | 2 (100.0) | 9 | 9 (100.0) | 6 | 3 (50.0) |
CIN1, cervical intraepithelial neoplasia 1; CIN2/3, cervical intraepithelial neoplasia 2/3; AIS, endocervical adenocarcinoma in situ; SCC, squamous cell carcinoma of cervix, ADC, invasive adenocarcinoma of endocervix; ADSQ, adenosquamous carcinoma of endocervix; SNEC, small cell neuroendocrine carcinoma of endocervix; hrHPV, high-risk human papillomavirus; #, number; y, years.